Deflux – world-leading niche product
Ever since the company was started, Q-Med has developed products for corrective use based on the NASHA™ technology. Several products have been first on the market and revolutionized the treatment available to patients where there were few alternatives.
One of these products is Deflux® that is used for the treatment of VUR – a malformation of the urinary bladder that affects children and which can give severe urinary tract infections and even irreversible kidney damage. Around one percent of all children are born with VUR. VUR can be cured by injecting Deflux into the wall of the urinary bladder, thus stopping the leakage of urine. Deflux was the first hyaluronic acid based product for the treatment of VUR and replaced less attractive alternatives such as Teflon. The largest single market for Deflux is the USA.
During 2009 Q-Med entered into global agreements with Oceana Therapeutics, LCC., to license worldwide commercialization rights to Deflux® and Solesta™. Included in this transaction are the exclusive rights to market, sell and distribute Deflux and Solesta and other products intended for the management of urological and gastroenterological conditions worldwide. Q-Med will continue to develop and manufacture all products under this agreement.
For more information on Deflux, please contact:
Salix Pharmaceuticals, Inc.
8510 Colonnade Center Drive
Raleigh NC 27615 USA